Beacon Investment Advisory Services Inc. Has $11.22 Million Stake in Gilead Sciences, Inc. $GILD

Beacon Investment Advisory Services Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 101,082 shares of the biopharmaceutical company’s stock after purchasing an additional 4,195 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Gilead Sciences were worth $11,220,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in GILD. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Activest Wealth Management boosted its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the second quarter valued at approximately $27,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the second quarter valued at $30,000. Finally, Putney Financial Group LLC increased its holdings in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the sale, the chief financial officer owned 153,503 shares of the company’s stock, valued at $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 136,257 shares of company stock valued at $16,723,492. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Down 0.8%

Shares of NASDAQ:GILD opened at $124.70 on Friday. The stock has a fifty day simple moving average of $122.95 and a two-hundred day simple moving average of $116.61. The stock has a market capitalization of $154.71 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 0.70 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Analyst Ratings Changes

GILD has been the topic of several recent analyst reports. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 20th. UBS Group raised shares of Gilead Sciences to a “hold” rating in a report on Thursday, December 4th. Truist Financial began coverage on shares of Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $131.54.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.